Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Leukemia, Myeloid, Acute 6Myelodysplastic Syndromes 3Leukemia, Myelomonocytic, Chronic 2Hematologic Neoplasms 2Solid Tumors 1

Interventions

Azacitidine 33venetoclax 10decitabine and cedazuridine drug combination 7Decitabine 7sabatolimab 3pevonedistat 3cedazuridine 3ON 01910 3spartalizumab 2glasdegib 2cc-486 2Panobinostat 2Cytarabine 2BI 6727 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2zanubrutinib 1triciribine 1tipifarnib 1terameprocol 1tapotoclax 1tagraxofusp 1ruxolitinib 1orludodstat 1navitoclax 1lonafarnib 1lintuzumab 1lenzilumab 1guadecitabine 1exatecan 1bisantrene 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia, Myelomonocytic, Chronic × glasdegib × Clear all
NCT02367456 2024-01-19

BRIGHT 1012

Pfizer

Phase 1 Completed
73 enrolled 31 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT04842604 2023-12-18

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Pfizer

Phase 3 Completed
14 enrolled 11 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡